作者
I Juhan-Vague, PE Morange, H Aubert, M Henry, MF Aillaud, MC Alessi, A Samnegard, E Hawe, J Yudkin, Maurizio Margaglione, Giovanni Di Minno, A Hamsten, SE Humphries
发表日期
2002/5/1
期刊
Arteriosclerosis, Thrombosis, and Vascular Biology
卷号
22
期号
5
页码范围
867-873
出版商
Lippincott Williams & Wilkins
简介
The thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described inhibitor of fibrinolysis that decreases plasminogen binding to the fibrin surface. The plasma TAFI concentration is almost entirely genetically determined. We investigated whether plasma TAFI levels and polymorphisms located in the TAFI gene could constitute risk markers of myocardial infarction (MI). Plasma TAFI antigen (Ag) levels were assayed by ELISA and 2 TAFI gene polymorphisms (Ala147Thr and C+1542G in the 3′ untranslated region) were determined in a large European case-control study. This study compared 598 men recruited 3 to 6 months after MI with 653 age-matched controls from North Europe (Stockholm, Sweden, and London, England) and South Europe (Marseilles, France, and San Giovanni Rotondo, Italy). A TAFI Ag value above the 90th percentile was associated with a significantly lower risk of MI (odds ratio 0 …
引用总数
200220032004200520062007200820092010201120122013201420152016201720182019202020212022123161822231519141810966242373